secwatch / observer
8-K filed March 29, 2024, 7:59 PM ET ticker CELC CIK 0001603454
debt confidence high sentiment neutral materiality 0.30

Celcuity Inc. (CELC): debt financing — Celcuity extends Term C Loan draw deadline to June 1, 2024 via Second Amendment with Innovatus

Celcuity Inc.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Celcuity Inc. amended credit facility of up to $75.0 million with Innovatus Life Sciences Lending Fund I, L.P..

Instrument
credit facility
Principal
up to $75.0 million
Counterparty
Innovatus Life Sciences Lending Fund I, L.P.
Event
amendment
Exact text from the filing
Amendment, shall be collectively referred to herein as the “Amended Loan Agreement”). As previously disclosed, the Amended Loan Agreement may provide the Company with up to $75.0 million through funding of up to five term loans. Funding of the first $15.0 million term loan occurred on April 8, 2021 in connection with entering into the original Loan
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Celcuity Inc. amended Second Amendment with Innovatus Life Sciences Lending Fund I, L.P. (effective 2024-03-29).

Action
amendment
Agreement
credit facility
Counterparty
Innovatus Life Sciences Lending Fund I, L.P.
Effective
2024-03-29
Exact text from the filing
On March 29, 2024, Celcuity Inc. (the “Company”) entered into a Second Amendment (the “Second Amendment”) to its existing Loan and Security Agreement (the “Loan Agreement”), dated April 8, 2021, between the Company and Innovatus Life Sciences Lending Fund I, L.P., a Delaware limited partnership (“Innovatus")
View on SEC.gov

299 debt financings filed in the last 30 days. Browse all debt financings →

Celcuity Inc. filing history →

Source: SEC EDGAR
accession 0001493152-24-012030
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.